Midatech Pharma announced that further to its announcement on 20 December 2018 (the 'Update Announcement') it has received feedback from the FDA on the regulatory study for its lead product MTD201 Q-Octreotide. The scenarios outlined for MTD201 in the Update Announcement included: 1. Single dose pharmacodynamic study in healthy volunteers. 2. Multi dose study in healthy volunteers. 3. Study in patients. The FDA feedback received indicates that Scenario 1 a single dose pharmacodynamic study in healthy volunteers would not support a new drug application. With this regulatory guidance the Company will now focus on Scenario 2. and 3. to determine the optimal study design for this final phase of the development of MTD201 to either establish equivalence of MTD201 versus Novartis' Sandostatin LAR ('SLAR'), or, the development of a differentiated product with an improved clinical profile. This could therefore include a multi dose study in healthy volunteers (Scenario 2), or a study in patients (Scenario 3). The final study protocol will be subject to the customary regulatory approvals. The MTD201 exploratory study conducted in 2018 has shown MTD201 to have a number of competitive advantages over SLAR, including smaller needle size, simpler and more reliable reconstitution and injection, reduced wastage and significantly lower manufacturing costs. The Q-Sphera technology used in MTD201 has patent protection through into the 2030s. Regulatory marketing authorisation submissions are currently planned for 2021 based on the Company's commercial manufacturing plan, and the Company expects to generate the required clinical data within this timeframe. With regards to the Company's cash position and further to the Update Announcement, the Company has very limited cash to enable it to continue as a going concern. Following this announcement, the Company will urgently look to conclude its discussions with the potential strategic investor described in the Update Announcement. There is no guarantee that the Company will be able to conclude these funding discussions on terms or quantum similar to those outlined in the Update Announcement or at all. Further announcements will be made as appropriate.